

**PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN
CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY
INVESTMENT CLIENTS)
Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code")**

1. KEY INFORMATION

(a) Full name of discloser:	Justin Ash
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): <i>The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.</i>	N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: <i>Use a separate form for each offeror/offeree</i>	Spire Healthcare Group plc
(d) Status of person making the disclosure: <i>e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)</i>	Person acting in concert with the offeree (Spire Healthcare Group plc)
(e) Date dealing undertaken:	18 May 2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? <i>If it is a cash offer or possible cash offer, state "N/A"</i>	N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing

Class of relevant security:	Ordinary shares of 1 pence each			
	Interests		Short positions	
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	1,652,131	0.41	Nil	-
(2) Cash-settled derivatives:	Nil	-	Nil	-
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:	Nil	-	Nil	-
TOTAL:	1,652,131	0.41	Nil	-

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b) Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists:	Ordinary shares of 1 pence each					
Details, including nature of the rights concerned and relevant percentages:	Scheme under which granted	Number of ordinary shares in respect of which options granted	Date of grant	Exercise price per share (£)	Vesting date	Expiry / lapse date
	2022 Long Term Incentive Plan	330,708	14 March 2022	Nil	14 March 2025**	13 March 2032
	2023 Long Term Incentive Plan	154,156***	15 March 2023	Nil	15 March 2026**	14 March 2033
	2024 Long Term Incentive Plan	542,575*	14 March 2024	Nil	14 March 2027**	13 March 2034
	2024 Deferred Share Bonus Plan	152,786	14 March 2024	Nil	14 March 2027	13 March 2034
	2025 Long Term Incentive Plan	759,173*	27 March 2025	Nil	27 March 2028**	26 March 2035
	2025 Deferred Share Bonus Plan	65,896	13 March 2025	Nil	13 March 2028	12 March 2035
	2026 Long Term Incentive Plan	736,733*	17 March 2026	Nil	17 March 2029**	16 March 2036
Notes: * Subject to satisfaction of performance conditions. ** Subject to a two-year holding period following the stated vesting date. *** This figure reflects the actual number of shares vested at the conclusion of the performance period. Options were granted for						

	541,661 shares at the date of grant.
--	--------------------------------------

3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

(i) Party to an offer or person acting in concert (except for a principal trader in the same group as a connected adviser)

Class of relevant security	Purchase/sale	Number of securities	Price per unit
N/A	N/A	N/A	N/A

(ii) Principal trader where the sole reason for the connection is that the principal trader is in the same group as a connected adviser

Class of relevant security	Purchases/sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
N/A	N/A	N/A	N/A	N/A

(b) Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii) Exercise

Class of relevant security	Product description e.g. call option	Exercising/exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d) Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing <i>e.g. subscription, conversion</i>	Details	Price per unit (if applicable)
Ordinary shares of 1 pence each	Exercise of share awards under the 2021 Long Term Incentive Plan	547,061 ordinary shares *	Nil
Ordinary shares of 1 pence each	Exercise of share awards under the 2023 Deferred Share Bonus Plan	116,473 ordinary shares **	Nil

* Processed on a net settlement basis whereby Spire Healthcare Group plc settles the tax and national insurance liabilities in connection with the exercise of the share awards under the 2021 Long Term Incentive Plan and the remaining balance of shares are allocated to Justin Ash. The number of shares allocated to Justin Ash following satisfaction of the taxes due is 289,942.

** Processed on a net settlement basis whereby Spire Healthcare Group plc settles the tax and national insurance liabilities in connection with the exercise of the share awards under the 2023 Deferred Share Bonus Plan and the remaining balance of shares are allocated to Justin Ash. The number of shares allocated to Justin Ash following satisfaction of the taxes due is 61,730.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person: <i>Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"</i>
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: <i>If there are no such agreements, arrangements or understandings, state "none"</i>
None

(c) Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)	NO
Supplemental Form 8 (SBL)	NO

Date of disclosure:	19 May 2026
Contact name:	Mantraraj Budhdev
Telephone number:	07787 283848

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.